IL-2 Signaling and CD4+ CD25+ Regulatory T Cells

  • Louise M. D’Cruz
  • Ludger Klein


Over the last two decades, our understanding of the function of Interleukin-2 (IL-2) has experienced several paradigmatic shifts. Although IL-2 was initially identified as a T cell growth factor, loss of function experiments clearly showed that it rather acts as a gatekeeper of immune homeostasis and tolerance. It is now widely accepted that the major non-redundant function of IL-2 is the maintenance of naturally occurring CD25+ Foxp3+ regulatory T cells (Treg). Importantly, this role as an essential survival factor may blur the interpretation of loss-of-function studies that tried to address other, mutually not exclusive functions of IL-2 in Treg biology, such as development and function. This chapter will summarize our current understanding of how IL-2 signaling may relate to these aspects of immune regulation by Treg.


Experimental Autoimmune Encephalomyelitis Immune Homeostasis Activation Induce Cell Death Responder Cell Treg Induction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Taniguchi, T., et al., Structure and expression of a cloned cDNA for human interleukin-2. Nature, 1983, 302(5906):305–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Yang-Snyder, J.A. and E.V. Rothenberg, Spontaneous expression of interleukin-2 in vivo in specific tissues of young mice. Dev Immunol, 1998, 5(4):223–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Granucci, F., et al., Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol, 2001, 2(9):882–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Sugamura, K., et al., The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. Annu Rev Immunol, 1996, 14: 179–205.PubMedCrossRefGoogle Scholar
  5. 5.
    Nelson, B.H. and D.M. Willerford, Biology of the interleukin-2 receptor. Adv Immunol, 1998, 70:1–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Eklund, J.W. and T.M. Kuzel, A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol, 2004, 16(6):542–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Pahwa, S. and M. Morales, Interleukin-2 therapy in HIV infection. AIDS Patient Care STDS, 1998, 12(3):187–97.PubMedCrossRefGoogle Scholar
  8. 8.
    Waldmann, T.A., The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol, 2006, 6(8):595–601.PubMedCrossRefGoogle Scholar
  9. 9.
    Schorle, H., et al., Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature, 1991, 352(6336):621–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Willerford, D.M., et al., Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity, 1995, 3(4):521–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Suzuki, H., et al., Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain. J Exp Med, 1997, 185(3):499–505.PubMedCrossRefGoogle Scholar
  12. 12.
    Sadlack, B., et al., Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell, 1993, 75(2):253–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Kramer, S., A. Schimpl, and T. Hunig, Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene. J Exp Med, 1995, 182(6):1769–76.PubMedCrossRefGoogle Scholar
  14. 14.
    Ma, A., et al., T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice. J Exp Med, 1995, 182(5):1567–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Van Parijs, L., et al., Functional responses and apoptosis of CD25 (IL-2R alpha)-deficient T cells expressing a transgenic antigen receptor. J Immunol, 1997, 158(8):3738–45.PubMedGoogle Scholar
  16. 16.
    Lenardo, M.J., Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature, 1991, 353(6347):858–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Zheng, L., et al., T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. J Immunol, 1998, 160(2):763–9.PubMedGoogle Scholar
  18. 18.
    Refaeli, Y., et al., Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity, 1998, 8(5):615–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Suzuki, H., et al., Normal thymic selection, superantigen-induced deletion and Fas-mediated apoptosis of T cells in IL-2 receptor beta chain-deficient mice. Int Immunol, 1997, 9(9): 1367–74.PubMedCrossRefGoogle Scholar
  20. 20.
    Leung, D.T., S. Morefield, and D.M. Willerford, Regulation of lymphoid homeostasis by IL-2 receptor signals in vivo. J Immunol, 2000, 164(7):3527–34.PubMedGoogle Scholar
  21. 21.
    D'Souza, W.N., et al., Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses. J Immunol, 2002, 168(11):5566–72.PubMedGoogle Scholar
  22. 22.
    Papiernik, M., et al., Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol, 1998, 10(4):371–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Malek, T.R., et al., CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity, 2002. 17(2):167–78.PubMedCrossRefGoogle Scholar
  24. 24.
    Almeida, A.R., et al., Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol, 2002, 169(9):4850–60.PubMedGoogle Scholar
  25. 25.
    Taniguchi, T., et al., IL-2 signaling involves recruitment and activation of multiple protein tyrosine kinases by the IL-2 receptor. Ann N Y Acad Sci, 1995, 766:235–44.PubMedCrossRefGoogle Scholar
  26. 26.
    Witthuhn, B.A., et al., Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature, 1994, 370(6485):153–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Johnston, J.A., et al., Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature, 1994, 370(6485):151–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Van Parijs, L., et al., Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity, 1999, 11(3):281–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Gaffen, S.L., et al., Distinct tyrosine residues within the interleukin-2 receptor beta chain drive signal transduction specificity, redundancy, and diversity. J Biol Chem, 1996, 271(35): 21381–90.PubMedCrossRefGoogle Scholar
  30. 30.
    Moriggl, R., et al., Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity, 1999, 11(2):225–30.PubMedCrossRefGoogle Scholar
  31. 31.
    Lin, J.X. and W.J. Leonard, The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene, 2000, 19(21):2566–76.PubMedCrossRefGoogle Scholar
  32. 32.
    Graves, J.D., et al., The growth factor IL-2 activates p21ras proteins in normal human T lymphocytes. J Immunol, 1992, 148(8):2417–22.PubMedGoogle Scholar
  33. 33.
    Miyazaki, T., et al., Pyk2 is a downstream mediator of the IL-2 receptor-coupled Jak signaling pathway. Genes Dev, 1998, 12(6):770–5.PubMedCrossRefGoogle Scholar
  34. 34.
    Friedmann, M.C., et al., Different interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferation. Proc Natl Acad Sci USA, 1996, 93(5):2077–82.PubMedCrossRefGoogle Scholar
  35. 35.
    Ravichandran, K.S., et al., Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin 2 signaling. Proc Natl Acad Sci USA, 1996, 93(11):5275–80.PubMedCrossRefGoogle Scholar
  36. 36.
    Blanchard, D.A., et al., Cdk2 associates with MAP kinase in vivo and its nuclear translocation is dependent on MAP kinase activation in IL-2-dependent Kit 225 T lymphocytes. Oncogene, 2000, 19(36):4184–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Merida, I., E. Diez, and G.N. Gaulton, IL-2 binding activates a tyrosine-phosphorylated phosphatidylinositol-3-kinase. J Immunol, 1991, 147(7):2202–7.PubMedGoogle Scholar
  38. 38.
    Augustine, J.A., S.L. Sutor, and R.T. Abraham, Interleukin 2- and polyomavirus middle T antigen-induced modification of phosphatidylinositol 3-kinase activity in activated T lymphocytes. Mol Cell Biol, 1991, 11(9):4431–40.PubMedGoogle Scholar
  39. 39.
    Kelly, E., et al., IL-2 and related cytokines can promote T cell survival by activating AKT. J Immunol, 2002, 168(2):597–603.PubMedGoogle Scholar
  40. 40.
    Ahmed, N.N., et al., Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci USA, 1997, 94(8):3627–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Jones, R.G., et al., Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J Exp Med, 2000, 191(10):1721–34.PubMedCrossRefGoogle Scholar
  42. 42.
    Reif, K., B.M. Burgering, and D.A. Cantrell, Phosphatidylinositol 3-kinase links the interleukin-2 receptor to protein kinase B and p70 S6 kinase. J Biol Chem, 1997, 272(22):14426–33.PubMedCrossRefGoogle Scholar
  43. 43.
    Brennan, P., et al., Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity, 1997, 7(5):679–89.PubMedCrossRefGoogle Scholar
  44. 44.
    Fontenot, J.D., et al., A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol, 2005, 6(11):1142–51.PubMedCrossRefGoogle Scholar
  45. 45.
    D'Cruz, L.M. and L. Klein, Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol, 2005, 6(11):1152–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Setoguchi, R., et al., Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med, 2005, 201(5):723–35.PubMedCrossRefGoogle Scholar
  47. 47.
    Burchill, M.A., et al., Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J Immunol, 2003, 171(11):5853–64.PubMedGoogle Scholar
  48. 48.
    Antov, A., et al., Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol, 2003, 171(7):3435–41.PubMedGoogle Scholar
  49. 49.
    Bensinger, S.J., et al., Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol, 2004, 172(9):5287–96.PubMedGoogle Scholar
  50. 50.
    Walker, L.S., et al., Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med, 2003, 198(2):249–58.PubMedCrossRefGoogle Scholar
  51. 51.
    Klein, L., K. Khazaie, and H. von Boehmer, In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci USA, 2003, 100(15):8886–91.Google Scholar
  52. 52.
    Romagnoli, P., D. Hudrisier, and J.P. van Meerwijk, Preferential recognition of self antigens despite normal thymic deletion of CD4(+)CD25(+) regulatory T cells. J Immunol, 2002, 168(4):1644–8.Google Scholar
  53. 53.
    Hsieh, C.S., et al., Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity, 2004, 21(2):267–77.PubMedCrossRefGoogle Scholar
  54. 54.
    Yu, A. and T.R. Malek, Selective availability of IL-2 is a major determinant controlling the production of CD4+CD25+Foxp3+ T regulatory cells. J Immunol, 2006, 177(8):5115–21.PubMedGoogle Scholar
  55. 55.
    Cheng, L.E., et al., Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death. Proc Natl Acad Sci USA, 2002, 99(5): 3001–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Fontenot, J.D., M.A. Gavin, and A.Y. Rudensky, Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 2003, 4(4):330–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Hori, S., T. Nomura, and S. Sakaguchi, Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003, 299(5609):1057–61.PubMedCrossRefGoogle Scholar
  58. 58.
    Wu, Y., et al., FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell, 2006, 126(2):375–87.PubMedCrossRefGoogle Scholar
  59. 59.
    Nakamura, K., A. Kitani, and W. Strober, Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med, 2001, 194(5):629–44.PubMedCrossRefGoogle Scholar
  60. 60.
    Piccirillo, C.A., et al., CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med, 2002, 196(2):237–46.PubMedCrossRefGoogle Scholar
  61. 61.
    de la Rosa, M., et al., Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol, 2004, 34(9):2480–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Thornton, A.M. and E.M. Shevach, CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med, 1998, 188(2):287–96.PubMedCrossRefGoogle Scholar
  63. 63.
    Thornton, A.M., et al., Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol, 2004, 172(11):6519–23.PubMedGoogle Scholar
  64. 64.
    Barthlott, T., G. Kassiotis, and B. Stockinger, T cell regulation as a side effect of homeostasis and competition. J Exp Med, 2003, 197(4):451–60.PubMedCrossRefGoogle Scholar
  65. 65.
    Furtado, G.C., et al., Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp Med, 2002, 196(6):851–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Liang, S., et al., Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med, 2005, 201(1):127–37.PubMedCrossRefGoogle Scholar
  67. 67.
    Thorstenson, K.M. and A. Khoruts, Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J Immunol, 2001, 167(1):188–95.PubMedGoogle Scholar
  68. 68.
    Mahnke, K., et al., Induction of CD4+/CD25+ regulatory T cells by targting of antigens to immature dendritic cells. Blood, 2003, 101(12):4862–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Chen, W., et al., Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 2003, 198(12):1875–86.PubMedCrossRefGoogle Scholar
  70. 70.
    Kretschmer, K., et al., Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol Rev, 2006, 212:163–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Kretschmer, K., et al., Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol, 2005, 6(12):1219–27.PubMedCrossRefGoogle Scholar
  72. 72.
    Knoechel, B., et al., Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med, 2005, 202(10):1375–86.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Institute for ImmunologyLudwig-Maximilians-University MunichGoethestrasse 31Germany

Personalised recommendations